This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Parkinson's Disease Treatment With Coenzyme Q10

This study has been completed.
Information provided by:
National Institute of Neurological Disorders and Stroke (NINDS) Identifier:
First received: February 25, 2000
Last updated: June 23, 2005
Last verified: December 2003
The purpose of this study is to compare the effects of varying dosage of coenzyme Q10 (CoQ10) versus a placebo in the treatment of Parkinson's disease (PD) in patients with early, untreated PD.

Condition Intervention Phase
Parkinson's Disease Drug: Coenzyme Q10 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effects of Coenzyme Q10 in Early Parkinson's Disease

Resource links provided by NLM:

Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Study Start Date: September 1998
Estimated Study Completion Date: October 2003
Detailed Description:
Four groups of 20 subjects/group of subjects will be randomly assigned to receive CoQ10 (at doses of 300, 600 or 1200 mg/day) or matching placebo. A subject must have early PD that does not require treatment. A subject will be evaluated at a Screening Visit, a Baseline Visit (after which the subject begins to take the study drug) and visits at 1, 4, 8, 12, and 16 months after the baseline visit. The subject will be followed until she/he needs treatment with levodopa or for a maximum of 16 months. Because CoQ10 is a component of the mitochondria (the part of a cell that makes energy), blood samples will be taken at the baseline visit and the last visit to study mitochondrial function.

Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subjects must have the three cardinal features of PD: slowness of movement, resting tremor and rigidity. The signs of PD must be greater on one side.

Exclusion Criteria:

  • Disorders that mimic PD.
  • Other serious medical problems.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004731

United States, New York
University of Rochester
Rochester, New York, United States, 14620
Sponsors and Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Clifford W. Shults, M.D. University of California, San Diego
  More Information Identifier: NCT00004731     History of Changes
Other Study ID Numbers: R01NS036714 ( U.S. NIH Grant/Contract )
Study First Received: February 25, 2000
Last Updated: June 23, 2005

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
Parkinson's disease
coenzyme Q10

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Coenzyme Q10
Growth Substances
Physiological Effects of Drugs
Vitamins processed this record on September 19, 2017